此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

新Enova预装式人工晶状体及推注系统装置的可靠性和有效性

2026年11月3日 更新者:Semih Çakmak、Istanbul University

新型Enova预载式人工晶状体及推注系统套装的可信度与有效性

Evaluation of the safety and efficacy of the new Enova® preloaded monofocal intraocular lens and cartridge injector system in cataract surgery

研究概览

详细说明

In this prospective and single-center clinical study, the safety and efficacy of the Enova PGF3 intraocular lens (IOL) and cartridge injector system will be evaluated.

The Enova PGF3 cartridge injector system is designed to be used in cataract surgeries. Cataract patients aged 40 years and older, both male and female, without any serious ocular disease other than cataracts, will undergo IOL implantation following cataract surgery. It is planned to perform a total of 200 implantations with either unilateral or bilateral implantation of the participants' eyes.

Postoperative visual acuity, refraction, patient satisfaction, and adverse events will be monitored during follow-up visits at day 1, week 1, and month 1.

The primary objectives of the study are to achieve an uncorrected distance visual acuity of 20/20 or better, and to maintain an error and complication rate related to the preloaded system below 7.5%. Secondary objectives include evaluating patient satisfaction and assessing whether surgeons find the preloaded system easy to use and if it meets their expectations.

The primary endpoints are refractive stability within ±0.50 D, uncorrected distance visual acuity of 20/20 or better, and a general clinical performance rating of the preloaded system with a score of 95% or higher. Secondary endpoints include the duration of surgery, accuracy of lens positioning, surgical complications, surgeon-reported ease of use, and patient satisfaction survey results meeting expectations.

As a safety parameter, adverse events reported in postoperative surgical reports will be evaluated.

研究类型

介入性

注册 (实际的)

200

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Fatih
      • Istanbul、Fatih、土耳其(türkiye)、34250
        • Istanbul University Istanbul Medical Faculty Ophthalmology Department

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

40年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Adults of either sex.

Age 40 years or older.

Willing and able to provide written informed consent and comply with planned study visits and procedures.

Healthy ocular status, with no ocular pathology other than cataract and mild refractive error.

Potential visual acuity of 20/32 (0.2 logMAR) or better in both eyes.

Presence of regular corneal astigmatism suitable for treatment with the study device.

Candidates for uncomplicated cataract surgery using the study device.

Exclusion Criteria:

  • Irregular corneal astigmatism (e.g., keratoconus).

Corneal pathology (e.g., scar, dystrophy, pterygium, moderate to severe dry eye).

Monocular conditions (e.g., amblyopia).

Previous corneal surgery, including radial keratotomy, corneal refractive surgery, corneal transplantation, DSAEK, or lamellar keratoplasty.

Previous anterior or posterior segment surgery (e.g., vitrectomy, laser iridotomy).

Diabetic retinopathy.

Macular pathology (e.g., age-related macular degeneration [ARMD], epiretinal membrane [ERM]).

History of retinal detachment.

Surgical complications that may affect study outcomes, such as:

Decentration due to capsulorhexis issues

Improper lens placement

Inadequate or missing postoperative capsular support

Posterior capsular rupture

Vitreous loss

Iris damage (tear, rupture, etc.)

Acute or chronic ocular diseases known to affect visual acuity or study outcomes (e.g., immunosuppressed state, connective tissue disease, clinically significant atopic disease, diabetes, or other systemic or ocular conditions).

Participation in any investigational drug or device study within 30 days prior to study start, or ongoing participation in another study.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Patients who need cataract surgery

Participants will undergo standard cataract surgery using the new preloaded intraocular lens (IOL) system. The intervention involves implantation of the preloaded IOL following routine phacoemulsification techniques.

This intervention uses a preloaded IOL delivery system, which allows for a single-use, sterile implantation during standard phacoemulsification cataract surgery. Unlike standard manually loaded IOLs, this system reduces preparation time and minimizes handling of the lens, potentially improving surgical efficiency and maintaining lens sterility.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Uncorrected Distance Visual Acuity (UDVA) - Photopic Conditions
大体时间:1 month postoperatively

Proportion of eyes achieving 20/20 or better uncorrected distance visual acuity under photopic conditions.

1 month postoperatively
Subjective Refractive Error
大体时间:1 month postoperatively

Eyes with a postoperative refractive error within ±0.50 diopters of the intended target.

1 month postoperatively
Overall Clinical Performance of the Preloaded IOL System
大体时间:1 month after surgery

Surgeon-rated assessment of the general clinical performance of the preloaded system by The ENOVA PGF3 Questionnaire. This questionnaire is a 14-item, study-specific, non-validated survey developed to evaluate surgeons' experience with an intraocular lens (IOL) preloaded delivery system. Eleven items are rated on a 5-point Likert scale with the following scoring structure:

  1. = Low
  2. = Below Expectation
  3. = Meets Expectation
  4. = Above Expectation
  5. = Outstanding Performance

Some additional items are Yes/No questions and do not contribute to the numerical total score.

The total numerical score is calculated by summing the 11 Likert-scaled items. Total score range: 11 to 55, with higher scores indicating better performance and more favorable user experience.

1 month after surgery

次要结果测量

结果测量
措施说明
大体时间
Preloaded System Evaluation Patient Questionnaire
大体时间:Baseline (preoperative) and 1 month postoperatively

Patient-reported outcomes assessing whether expectations for visual improvement and overall satisfaction were met.The questionnaire consists of 14 items assessing a patient's self-reported difficulty in performing vision-related daily activities. Each activity is rated using a 0-4 scale, where:

4 = No difficulty

3 = Mild difficulty

2 = Moderate difficulty

1 = Severe difficulty

0 = Unable to perform the activity

The total score is calculated by summing responses across all 14 items. Total possible score range: 0 to 56

Higher scores indicate better visual function and less activity limitation.

Lower scores indicate worse visual function.

Baseline (preoperative) and 1 month postoperatively
Surgical Procedure Assessment
大体时间:Intraoperative

Surgeon-reported ease of lens implantation and accuracy of lens placement, evaluating whether expectations for procedural handling were met.The surgeon notes, during the operative visit, the location of the incision, the size of the incision, whether the implantation system is compatible with the wound site, how many seconds the implantation time is shortened, and whether there were any issues with the unfolding of the intraocular lens or its placement into the capsular bag.

Intraoperative

其他结果措施

结果测量
措施说明
大体时间
Serious Adverse Events
大体时间:1 month postoperatively

Any serious adverse events occurring during surgery or within 1 month after surgery.

1 month postoperatively
Postoperative Inflammation
大体时间:1 week and 1 month postoperatively

Assessment of inflammation levels by biomicroscopic anterior chamber and vitreus examination according to Standardization of Uveitis Nomenclature (SUN) International Workshop Grading System

1 week and 1 month postoperatively
Intraocular Pressure,
大体时间:1 week and 1 month postoperatively

Intraocular pressure is assessed via Goldmann Applanation Tonometry. Normal levels are accepted as 10-21 mmHG.

1 week and 1 month postoperatively

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年5月10日

初级完成 (实际的)

2026年6月1日

研究完成 (实际的)

2026年7月1日

研究注册日期

首次提交

2025年8月26日

首先提交符合 QC 标准的

2025年12月3日

首次发布 (实际的)

2025年12月17日

研究记录更新

最后更新发布 (实际的)

2026年11月4日

上次提交的符合 QC 标准的更新

2026年11月3日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

其他研究编号

  • IstanbulUni

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

IPD 计划说明

Individual participant data will not be shared outside the study.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅